News From CanRIO

Hot off the Press!

Posted November 10, 2020

CanRIO has just published its second national case series. This retrospective cohort study included 27 patients with pre-existing autoimmune disease (PAD) treated with immunotherapy. Consistent with previously published studies, PAD exacerbations were common, however generally mild and manageable. Compared to our Canadian cohort without PAD, there were higher rates of cancer progression 40% versus 15% over the follow-up period. This raises concerns about potential impacts of immunosuppression in those with PAD and its effect on immunotherapy efficacy. Read more about this and other relevant studies in the Research section.